Hanmi Fine Chemical, a subsidiary of Hanmi Pharmaceutical Group specializing in active pharmaceutical ingredients (APIs) development and manufacturing, is expanding its services from APIs to “high-tech” contract development and manufacturing organization (CDMO) services. Due to the COVID-19 pandemic, there has been an increase in the global demand for high-level, synthetic biopharmaceutical raw materials, such as those used in mRNA vaccines, including lipid nanoparticles (LNP), nucleotides, c...